Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 20/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
| ▸ | RARA | P10276 | 2/20 | 0.42 |
| ▸ | RARB | P10826 | 2/20 | 0.42 |
| ▸ | RARG | P13631 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2660380 | 0.87 | GCK (0.65) | GCKKCNH2RARARARBRARG | |
| SCHEMBL1427153 | 0.87 | GCK (0.65) | GCKKCNH2RARARARBRARG | |
| SCHEMBL1427229 | 0.82 | GCK (0.64) | GCKKCNH2RARARARB | |
| SCHEMBL4783311 | 0.82 | GCK (0.64) | GCKKCNH2RARARARB | |
| SCHEMBL1427361 | 0.82 | GCK (0.51) | GCKKCNH2RARARARBRARG | |
| SCHEMBL2654780 | 0.79 | CHRNB2 (0.48) | GCKKCNH2 | |
| SCHEMBL2662313 | 0.78 | GCK (0.53) | GCKKCNH2RARARARBRARG | |
| SCHEMBL1042208 | 0.78 | GCK (0.53) | GCKKCNH2RARARARBRARG | |
| SCHEMBL1427125 | 0.77 | GCK (0.51) | GCKKCNH2RARARARBRARG | |
| SCHEMBL1653673 | 0.77 | GCK (0.51) | GCKKCNH2RARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1902052-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007007041-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |